Table I.

Treatment outcomes and adverse events from sc alemtuzumab therapy in patients with acquired bone marrow failure.

N = 59	Treatment outcomes (%)
ORR	63
CR	36
PR	27
Age
<60 years	64·5
>60 years	61
Diagnosis
AA	60
PRCA	62
T-LGL	60
IN/PWCA	100
Disease status
Treatment na€ıve	71
Relapsed	65
Refractory	52
Therapy discontinuation*
Injection reaction	1
Patient preference	3
Adverse events
Injection reactions	20
Infections	29
Clonal events	6

AA, aplastic anaemia; CR, complete response; IC, immune cytopenia; ORR, overall response rate; PR, partial response; PRCA, pure red cell aplasia; PWCA, pure white cell aplasia; T-LGL, T-cell large-granular lymphocytic leukaemia.

^*4 discontinued treatment.